News Articles

Tidings of comfort and joy can take on a different meaning during the holidays as a cancer patient. With so much focus needed to manage your diagnosis and the effects of cancer and treatment, it may be hard or even impossible to maintain some of your family’s beloved holiday traditions. Shail Dalal, M.D., Texas Oncology–Palestine Cancer Center, Srinath Sundararajan, M.D., FACP, Texas Oncology–Katy, Bellville and Sealy, and Bridget O’Brien, D.O., FACS, FSSO, Texas Breast Specialists–Cedar Park and Georgetown share how to talk about the holidays with your children and tips for parenting with cancer this holiday season.

In The Jewish Outlook's annual special section highlighting business and professional women, Karen Cohen, M.D., radiation oncologist at Texas Oncology–Austin Central and Round Rock, discusses her career as a women, what inspires her on the job and more.

Officials from Texas Oncology-Tyler, Christus Health, city and Smith County officials and other dignitaries were on site for the grand opening of the state-of-the-art facility. The 85,000-square-foot Northeast Texas Cancer and Research Institute in Tyler will include clinic space for medical oncology, hematology, gynecologic oncology, radiation oncology, and nearly 3,000 square feet of dedicated clinical research space. 

Christus Health and Texas Oncology's collaborative cancer center in Tyler is hosting a grand opening ceremony tonight, November 29th. The 85,000-square-foot Northeast Texas Cancer and Research Institute in Tyler will include clinic space for medical oncology, hematology, gynecologic oncology, radiation oncology, and nearly 3,000 square feet of dedicated clinical research space. 

Officials from Texas Oncology-Tyler, Christus Health, city and county officials, and other dignitaries were on site for the grand opening of the state-of-the-art, world-class facility that will be a game-changer for patients and their families. The new 85,000-square-foot institute will include clinic space for medical oncology, hematology, gynecologic oncology, radiation oncology and a clinical research space.

As a result of the pandemic, less people are going into doctors’ offices for their annual checkups and screenings, leading to more cancer diagnoses being caught late. Dr. Shail Dalal, M.D., Texas Oncology–Palestine, shares more about the importance of breast cancer screenings and early detection.

A diagnosis, treatment plan, or return of breast cancer can impact all aspects of your life. As you adjust to the physical, emotional, and psychological changes that come with cancer, you also must decide when and how to tell your family, friends, and broader support system. Tanyel S. Williams, LMSW, ACSW, CHW, ACHP-SW, OSW-C, Texas Oncology–Palestine Cancer Center, shares how to have a conversation about breast cancer with your loved ones.

A Medscape poll of over 200 physicians showed that insurers denied up to 60% of their prior authorizations, and most believe that denials delayed treatment or diagnostic tests. Debra Patt, M.D., Ph.D., MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology, discusses with Medscape how the prior authorization process can cause delays in patient care and how she manages patients’ expectations.

In 2020, 68-year-old Robert Walker was diagnosed with stage IV pancreatic cancer, which typically has a poor prognosis with less than five percent of patients expected to survive more than five years. Through good days and not-so-good days, Robert maintained a positive attitude. Thanks to the multidisciplinary care he received from Texas Oncology, Robert has responded so well to every component of treatment from chemotherapy to surgery, that he has far outlived the traditional survival for patients with stage IV pancreatic cancer as he continues to fight this deadly disease.

According to Debra Patt, MD, PhD, MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology, results from the DESTINY-Breast04 clinical trial continue to make waves in breast cancer care—while raising considerations for payers and a need for education among doctors. Dr. Patt offered the keynote address at ASCO’s Patient-Centered Oncology Care®, highlighting the dramatic responses seen with trastuzumab deruxtecan in the trial.